TPO

Avatrombopag (YM477) is a new oral thrombopoietin (TPO) receptor agonist, activating TPO receptor and increasing megakaryocytic proliferation/differentiation and platelet production.

TPO agonist 1, a thrombopoietin agonist, is useful as a promoter of thrombopoiesis and megakaryocytopoiesis for the treatment of thrombocytopenia.

TPO-L is a photoinitiator used in 3D printing resins, facilitating two-photon induced polymerization. The two-photon absorption cross-section spectrum of Lucirin TPO-L exhibits a peak of 1.2 GM at 610 nm. Although the two-photon absorption cross-section is relatively small, Lucirin TPO-L demonstrates a high polymerization quantum yield.

TPOP146 is a selective CBP P300 benzoxazepine bromodomain inhibitor with Kd values of 134 nM for CBP and 5.02 μM for BRD4.

(S)-ATPO is Competitive antagonist at GluR1-4 (AMPA-preferring) receptors.

NTPO trisodium induces DNA damage and fragmentation, activating ATR-mediated cell cycle checkpoints. Its DNA damaging effects are mitigated by base excision repair (BER) but not by nucleotide excision repair (NER) [1].

MPO-IN-1 is an orally active myeloperoxidase (MPO) inhibitor, inhibiting MPO and thyroid peroxidase (TPO). It is useful in inflammation research.

Butyzamide is an effective and oral Mpl activator. It is a novel non-peptide-based molecule with antagonistic effects on thrombopoietin (TPO) receptors, which promotes proliferation of human Mpl (hMpl) expression and mouse pro B cell line Ba F3. The phosphorylation of JAK2, STAT3, STAT5 and MAPK is induced. Butyzamide has been shown to help increase platelet levels in mouse xenotransplantation trials.

Eltrombopag (SB-497115-GR), an orally active thrombopoietin receptor agonist with megakaryopoiesis stimulating activity, binds to and stimulates the platelet thrombopoietin receptor (TPO-R or CD110).

Eltrombopag Olamine (Eltrombopag diethanolamine salt) is an orally active small-molecule, nonpeptide thrombopoietin receptor agonist that stimulates megakaryopoiesis. It binds to and activates the transmembrane domain of the platelet thrombopoietin receptor (TPO-R or CD110), promoting the proliferation and differentiation of megakaryocytic cells and enhancing platelet production.

4”-O-Glucosylvitexin is a naturally derived compound that inhibits TPO activity. It is extracted and purified from the fruit of hawthorn (Crataegus pinnatifida).

Hetrombopag olamine is a non-peptide thrombopoietin (TPO) receptor agonist with oral activity.

(E/Z)-Eltrombopag 13C4 ((E/Z)-SB-497115 13C4) is a mixture complex of E-Eltrombopag and Z-Eltrombopag, with 13C labeled. Z-Eltrombopag is a thrombopoietin (TPO) receptor agonist developed for certain conditions that lead to thrombocytopenia.

4 -O-Glucosylvitexin (glucosylvitexin) inhibits TPO activity.

Avatrombopag hydrochloride (AKR-501) is an orally active, nonpeptide agonist of the thrombopoietin (TPO) receptor with an EC50 of 3.3 nM. It effectively mimics TPO by stimulating platelet production through activation of the intracellular signaling system, facilitating platelet and megakaryocyte generation from hemopoietic precursor cells. Additionally, Avatrombopag hydrochloride serves as a substrate for cytochrome P450 [CYP] 2C9 and CYP3A.

MPO-IN-4 (compound 12) is a potent and selective myeloperoxidase (MPO) inhibitor with an IC50 of 25 nM and also demonstrates inhibition of thyroid peroxidase (TPO) with an IC50 of 2.2 μM. MPO-IN-4 has no effect on methyl guanine methyl transferase (MGMT) [1].

Rafutrombopag, a thrombopoietin (TPO) agonist, is a chemical compound.

Totrombopag, also known LGD-4665, GSK2285921 and SB559448, is an oral thromobopoietin receptor agonist, is being developed as a new generation small molecule thrombopoietin (TPO) mimetic. It is a highly selective and potent agonist of the TPO receptor and therefore induces differentiation and proliferation of megakaryocytes. The pharmacologic characteristics indicate potential therapeutic use in thrombocytopenic patients with a variety of clinical etiologies.

Avatrombopag, also known as AKR-501, YM477, AS 1670542 or E5501, is a novel orally-active thrombopoietin (TPO) receptor agonist. AKR-501 specifically targeted the TPO receptor and stimulated megakaryocytopoiesis throughout the development and maturation of megakaryocytes just as rhTPO did. AKR-501 may be useful in the treatment of patients with thrombocytopenia. Avatrombopag was first approved in 2018.

Eltrombopag Methyl Ester, a derivative of Eltrombopag, functions as a thrombopoietin (Tpo) receptor agonist to enhance platelet production and is employed in the study of certain thrombocytopenia variants.

Romiplostim is a peptide-body (peptide-body) molecule and an Fc peptide fusion protein analog of TPO (thrombopoietin protein). It functions by activating the thrombopoietin receptor (TPO receptor) to increase platelet production.

Avatrombopag-d8 is a deuterated compound of Avatrombopag. Avatrombopag has a CAS number of 570406-98-3. Avatrombopag is a new oral thrombopoietin (TPO) receptor agonist, activating TPO receptor and increasing megakaryocytic proliferation differentiation and platelet production.

Lusutrombopag-d13 is a deuterated compound of Lusutrombopag. Lusutrombopag has a CAS number of 1110766-97-6. Lusutrombopag is an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist for chronic liver disease (CLD) patients with thrombocytopenia prior to elective invasive surgery.

Lusutrombopag (Mulpleta) is an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist for chronic liver disease (CLD) patients with thrombocytopenia prior to elective invasive surgery.